The Comparasion Tenofovir Disoproxil Fumarate with Telbivudine or lamivudine in Preventing Hepatitis B Transmission in Mothers with High Viral Load: A Retrospective Cohort Study

Background Little observational data exist regarding the comparasion of efficacy and safety between tenofovir disoproxil fumarate(TDF) and Telbivudine(Ldt) in late pregnancy on preventing hepatitis B mother-to-child transmission (MTCT) in real-world settings. Methods We retrospectively enrolled HB-s antigen (HBsAg) positive mothers with HBV DNA ≥2*10 5 IU/mL to receive TDF or LdT after gestational weeks 24~32 weeks. All infants received standard immunoprophylaxis. The primary outcomes were the MTCT rates at infants’ age of 52 weeks and the safety of TDF or LdT use. The secondary outcomes were the decline of HBV-DNA levels at delivery and the rates of on-treatment and off-treatment alanine aminotransferase (ALT) elevation>2 uper limit normal(ULN) during the study. Results Of 1407 patients enrolled, 209 patients received TDF treatment and 1198 patients received LdT treatment. There were no difference between the mean duration of TDF and Ldt treatment (TDF vs.LdT: 11.76±2.20 weeks vs 11.64±2.79 weeks, P >0.05) .At birth, 9.8% of infants in the TDF-treatment group were HBsAg positive, lower than 20.8% in the LDT-treatment group (P<0.001). Among 1405 infants (TDF/LdT=213/1192) of the 1385 (TDF/LdT=205/1180) patients completed the 52-week study, intention‐to‐treat analysis indicated 0.5% (1 infant was lost to follow-up) in TDF treated mother and 0.3% in LDT treated mothers (3 infant was lost to follow-up). There was no difference between TDF group and LdT(P>0.05). On-treatment analysis indicated 0% of HBsAg positive infants in the three group (P>0.05). The levels of HBV-DNA decline in TDF-treated mothers were observed comparable in LdT treated mother (4.05±0.93 log 10 IU/ml vs.3.99±1.30 mothers(7.3% vs.15.7%, P < 0.05). Alanine aminotransferase flares in TDF-treated mothers were observed lower than LdT-treated mothers(7.3% vs.15.7%, P < 0.05) . Conclusions TDF and LdT use in late pregnancy for highly viremic mothers was equally effective in reducing MTCT. TDF treated mothers complained more symptoms of disgestive systemmore and had less ALT abnormalities than LdT.


Introduction
Mother-to-child transmission of hepatitis B virus (HBV) is the major causes of chronic Hepatitis B virus (CHB) which is associated with high rates of liver cirrhosis and hepatocellular carcinoma [1][2] . Although reduced from 90% to approximately 5%-10% [3][4] with combination use of HBV vaccine and Hepatitis B immunoglobulin G, MTCT remains a threat of infants born to women with a high HBV viral load (>200,000 IU per milliliter) and results in significant numbers of chronic infant infection for a large carrier rates of HBV in Southeast Asian [5][6][7] .Previous studies indicated that inhibiting HBV replication with lamivudine (LAM), telbivudine (LdT) or tenofovir disoproxil fumarate (TDF) during late pregnancy in highly viremic mothers could further reduce the risk of MTCT [8][9][10] . However, little observational data exists regarding the comparasion of efficacy and safety between tenofovir TDF and Ldt in late pregnancy on preventing MTCT of HBV.
In our previous study [9] , LdT-treated mothers had a mean serum HBV DNA decline >4 log10 copies/mL at deivery after 10.38±1.02 weeks' treatment, compared to no change in HBV DNA levels for the untreated group (P<0.001).Infants of Ldt-treated mothers had lower HBV MTCT rates than infants of untreated mothers in HBeAg positive mothers with HBV DNA >6 log10 copies/mL.The incidence of Alanine aminotransferase flares ((>5 times baseline level or >10 times ULN) were higher in Ldt and LAM treated mothers than untreated mothers ( (17.1% vs. 6.3%, P < 0.001). In the randomised controlled trial (RCT) by Pan et al [10] , TDF-treated patients could achieved 3.56 log10IU/ml HBV DNA reduction of at delivery after 8.57±0.53 weeks' treatment and yield a successful result on HBV MTCT in HBeAg positive mothers with an HBV DNA level >200 000 IU/mL. TDF treated patients had more frequent alanine aminotransferase elevations above the normal range than untreated mothers (45% vs. 30%, P = 0.03). However, in another study about TDF,incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P = 0.29) [11] .
Because there was lack of the comparasion of the MTCT rates in different NAs treated population and the same criteria of abnormal ALT elevation in these studies.We conducted a retrospective cohort study with a sample size of 1637 patients to to assess the safety and efficacy of third-trimester use of TDF versus LdT, based on the patient-physician decision in a real-life MTCT prevention setting.

Study design and Patient Selection
We conducted a retrospective cohort study to assess the safety and efficacy between TDF Pregnant subjects were screened for the following eligibility criteria: age between 20 and 45 years; HBs antigen (HBsAg) and HBeAg positivity; HBV DNA levels ≥2*10 5 IU/mL;written the informed consent before treatment;antiviral therapy started on oral LdT 600 mg or TDF 300 mg between gestational weeks 24 and 32; paired infants administered 200 IU of

Data Collections and Outcome Measurements
Demographic and clinical data were extracted from the electronic clinical record and paper charts.Data were assessed at the following time points: 4-week intervals from baseline information to delivery; postpartum weeks 4-8, 12, 24, and 28-52.The following data from the clinic and inpatient services were collected for analysis: age, initiating administration weeks, treatment duration before delivery,pregnancy and obstetric complications, pertinent physical findings and laboratory information which include HBV virological markers, chemistry panel results, and imaging results.
The two primary outcomes were the rates of mother to child transmission and the safety of TDF or LdT use at postpartum week 52. The rate of mother-to child transmission was defined as the proportion of infants who had a serum HBV DNA level of more than 20 IU per milliliter (i.e., above the lower limit of detection) or who were positive for hepatitis B surface antigen (HBsAg) at 52 weeks.The rates of ALT leation were the rates of 2 times ULN during the treatment or follow-up.AEs were graded according to the Common Terminology Criteria for Adverse Events (version 4.0). Cases of a structural defect or other safety reports in newborns or infants were tabulated using data acquired from infant during the prenatal period or the postnatal period up to 28 weeks of age (e.g., ultrasonography examination, reports of birth defects and APGAR scores, measurements from growth charts, and development milestones).Perinatal and partum complications (e.g., hypertensive disorders in pregnancy, gestational diabetes mellitus, fetal growth retardation, premature delivery, premature rupture of membrane and postpartum hemorrhage) were included in the safety analysis.
The secondary outcomes were the decline of HBV-DNA levels at delivery and the rates of on-treatment and off-treatment alanine aminotransferase (ALT) elevation>2 uper limit normal(ULN) during the study.

Statistical Analysis
The intention to treatment analysis was defined as analysis included all enrolled patients, including those with protocol deviations. We included all enrolled infants to perform ITT analysis of the MTCT rates. Data of mothers and infants who were lost to follow-up were still included in the analysis.Infants who were lost to follow-up were counted as having treatment failure. Baseline characteristics and laboratory results were summarized for two groups by means of descriptive statistics, including percentage, means ±standard deviation (SD), and 95% CI. For the quantitative variable, the t-test was used to compare group differences. For categorical variables, the chi-square test was used for group comparisons. Significance level was set at P < 0.05; all data were analyzed by SPSS 23.0 (SPSS, IBM., NewYork).

Study Population
1767 pregnant women were screened and 1407 mothers were enrolled into the study. infants completed the 52-week follow-up.The disposition of our study patients is shown in Figure. 1.The characteristics of mother at baseline and infants at birth were presented in Table 1. The mean (±SD) gestational age at drug initiating was 27.38±1.84 weeks and 27.52±1.13 weeks in patients who received TDF and LDT,respectively. The mean(+SD) duration of treatment was11.76±2.20 weeks and 11.64 ± 2.79 weeks for patients who received TDF and LDT, respectively.

Efficacy of Mothers and Infants
Before delivery, the levels of HBV-DNA decline in TDF-treated mothers were observed comparable in LdT treated mother (4.05±0.93 log 10 IU/ml vs.3.99±1.30 log 10 IU/ml, P> 0.05).All infants in the study received HBIg with first dose of HBV vaccine within 2 hours of birth and completed the addition two vaccines as per standard of care, except for 4 infant who returned to the local city to complete the third dose of vaccine and was lost to follow up. At birth, the HBsAg positive rate of infants in the TDF-treatment group were lower than in the LDT -treatment group (9.8% vs.20.8%, P<0.001).

Safety Assessment
All mothers in the current study tolerated treatment well without discontinuation of treatment due to adverse event(s). During the treatment period, 18 mothers (TDF/LdT = 15/3) withdrew from the study after receiving the first dose of medication.All withdrawals were for because of family relocation to other cities, except for 1 LdT treated patient who  (Table 2) and ALT elevation Table 3). Compared to AEs in LdT treated group, nausea,anorexia and dizziness occurred more often in TDF treated patients.
However, more mothers complained of arthralgia in LdT treated group than in TDF treated group. All AEs reported were grade I-II and there were no maternal severe AEs observed in three group. There were no differences in the incidence of other AEs between TDF treated mothers and LdT treated mothers.
There was no difference in the ALT elevation between TDF and LDT treated mothers (1% vs. 0.7%, P = 0.647) during the treatment. (Table 3). Also, no difference were found in the

Discussion
In this study, we report the data on different antiviral drugs for preventing MTCT in highly viremic mothers in real-world setting, which is the first and largest real-life study about the comparasion of antiviral treatment between TDF and LdT in pregnant mothers. TDF or LdT were recommended to prevent MTCT in high viremic population during pregnancy in many guidelines for the managementof chronic HBV infection. However, there is no priority recommendation among them for the lack of regarding studies on the selection of TDF or LdT [6,[12][13][14][15] .
The use of TDF and LdT during pregnancy yielded 100% successful rate of preventing MTCT in the on protocol analysis in our real-life setting, respectively.Same to previous studies [8][9][10][16][17][18] , our data further support the use of TDF, or LdT during late pregnancy on preventing MTCT in CHB mothers with high levels of HBV DNA. At birth, the HBsAg positive rate of infants in the TDF-treatment group were lower than in the LDT -treatment group.
The mean gestational age at drug initiating and duration of treatment was similar between patients who received TDF and LDT. Before delivery, the levels of HBV-DNA decline in TDFtreated mothers(4.05±0.93 log 10 IU/ml) were observed comparable in LdT treated mother (3.99±1.30 log 10 IU/m). At birth, the HBsAg positive rate of infants in the TDF-treatment group were lower than in the LDT -treatment group (9.8% vs.20.8%, P<0.001).
Many studies [8][9][10][11][19][20] observed the safety profiles of LdT or TDF and the antiviral treatment were tolerated well during pregnancy.There were no differences in the rates of birth defect and fetus or infant complication between patients received TDF or LdT antiviral treatment and none antiviral treatment during pregnancy. However, previous study was underpowered to evaluate potentially small differences in birth-defect rates.
Our study, with a much larger sample size of infants (TDF/LdT = 214/1195), identified a similar AEs profile with those data published in previous studies [8][9][10][11][19][20] . Although there were no differences between the MTCT rates and birth defect rates, the rates of offtreatment ALT elevations were more often in LdT treated mothers than in TDF-treated mothers. TDF treated mothers had complained more symptoms of.nausea,anorexia and dizziness and less arthralgia than LdT treated mothers. Congenital deformities was reported in 0.3% of infants in the LdT group which was not higher than the common population [21][22] .

Conclusions
In conclusion, our results indicated that TDF or LdT treatment yielded the similar success in preventing MTCT in CHB mothers with HBV DNA ≥2*10 5 IU/mLduring late pregnancy.
TDF had a lower rate of off-treatment ALT elevations than LdT.

Consent for publication: Not applicable.
Availability of data and materials The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. We will also upload our data to Chinese Clinical Trial Registration wITHIN SIX MONTHS AFTER THE TRIAL COMPLETE.  MTCT, mother-to-child transmission; ITT, Intention-to-treat; PP, per-protocol.  Disposition of mothers and infants